<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177110</url>
  </required_header>
  <id_info>
    <org_study_id>ICORG 13-22</org_study_id>
    <nct_id>NCT02177110</nct_id>
  </id_info>
  <brief_title>A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma</brief_title>
  <acronym>SYS-ACT</acronym>
  <official_title>A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Responsiveness in Advanced or Metastatic Malignant Melanoma (SYS-ACT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory prospective translational multicentre study. Melanoma is the 5th most
      common cancer diagnosed in Ireland and its incidence among women and men is above the
      European average.

      Following treatment the elimination of cancer cells ultimately occurs by the activation of
      apoptotic cell death pathways. The SYS-ACT approach builds on a combination of mathematical
      systems of modelling, quantitative biochemistry and cell biology, and specifically predicts
      the drug responsiveness of melanoma cell lines to various apoptosis-inducing treatments.

      The investigators propose to validate the SYS-ACT approach and application in a translational
      systems medicine study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of SYS-ACT</measure>
    <time_frame>2 years</time_frame>
    <description>Validate the predictive capacity of SYS-ACT by assessing responsiveness to treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression free survival (PFS) and overall survival will be assessed for each patient for up to 2 years.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Advanced Melanoma</condition>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Study</arm_group_label>
    <description>Patients who have fresh frozen and FFPE tissue taken prior to treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Fresh frozen tissue and FFPE tissue is available</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fresh frozen and FFPE tissue samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients must have a diagnosis of advanced or metastatic melanoma of the skin
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients â‰¥ 18 years of age.

          2. Patient must be able to give own signed informed consent.

          3. Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of
             the skin.

          4. Patients that are planned to receive either:

               -  Adjuvant treatment

               -  1st line treatment for metastatic disease

               -  2nd line treatment for metastatic disease

          5. Patients with prior adjuvant treatment are allowed.

          6. Patients receiving planned standard treatment of one or more of the following:

               -  Chemotherapy regimens containing DTIC, TMZ and/or cisplatin

               -  Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)

               -  BRAF and/or MEK inhibitors

          7. Patients were FFPE and fresh frozen tissue is available (both mandatory).

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>021-4922000</phone>
    </contact>
    <investigator>
      <last_name>Derek Power, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hosptial</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>01-8093000</phone>
    </contact>
    <investigator>
      <last_name>Bryan Hennessy, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital and Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>01-8032000</phone>
    </contact>
    <investigator>
      <last_name>David Gallagher, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>01-2214000</phone>
    </contact>
    <investigator>
      <last_name>John Crown, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>091-524222</phone>
    </contact>
    <investigator>
      <last_name>Paul Donnellan, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waterford Regional Hospital</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>051-848000</phone>
    </contact>
    <investigator>
      <last_name>Paula Calvert, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced melanoma</keyword>
  <keyword>metastatic melanoma</keyword>
  <keyword>fresh frozen tissue</keyword>
  <keyword>FFPE tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

